## A: Agilent Technologies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -4.5% below STRENGTH zone (4.0-10.0%); PEG 2.16 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($137.23)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Agilent and Monash University Malaysia Mark 15-Year Partnership with New BioDiscovery Hub to Drive Regional Biotech Innovation**
- Source: Laotian Times | 20251205T010957 | Bullish | Relevance: 100%
- Agilent Technologies and Monash University Malaysia have expanded their 15-year partnership, establishing a new MUMPMP-Agilent BioDiscovery Hub. This collaboration aims to accelerate R&D in small- and large-molecule analysis, enhancing biotechnology research and innovation in the Asia-Pacific region. The hub will deploy advanced Agilent analytical instruments to support research programs, applications development, and scientific training.

**2. Agilent and Monash University Malaysia Mark 15-Year Partnership with New BioDiscovery Hub to Drive Regional Biotech Innovation**
- Source: Yahoo Finance | 20251205T013648 | Bullish | Relevance: 100%
- Agilent Technologies Inc. and Monash University Malaysia have strengthened their 15-year partnership by establishing the MUMPMP-Agilent BioDiscovery Hub. This collaboration aims to accelerate regional biotechnology research and innovation, focusing on small- and large-molecule analysis in biomedical, pharmaceutical, and molecular biology fields. The hub will be equipped with Agilent's advanced LC/MS and GC/MSD systems to support research programs, applications development, and scientific training, reinforcing Malaysia's role as a biotech innovation hub.

**3. Jim Cramer on Agilent: "The Thing's Just Caught Fire"**
- Source: Finviz | 20251204T120500 | Bullish | Relevance: 100%
- Jim Cramer highlighted Agilent Technologies (NYSE: A) as a stock that has "caught fire," despite a period of choppiness for the life sciences industry post-pandemic. He noted the company's 55% surge from April lows, a solid quarter with 7% organic growth, and encouraging signs of a business turnaround driven by reshoring in life sciences manufacturing and novel medicine requirements. Cramer also mentioned that the Trump FDA under RFK Jr. has been less disruptive than expected on Wall Street.

**4. How Is Agilent Technologies' Stock Performance Compared to Other Healthcare Stocks?**
- Source: Markets Financial Content | 20251204T065000 | Somewhat-Bullish | Relevance: 100%
- Agilent Technologies (A) has shown mixed stock performance, outperforming The Health Care Select Sector SPDR Fund (XLV) over the past three months and 52 weeks but lagging XLV year-to-date. Despite strong Q4 2025 results and a positive fiscal 2026 outlook, its stock performance trails industry peer Eli Lilly and Company (LLY). Analysts hold a "Moderate Buy" rating with a price target suggesting a 13.6% upside.

**5. Dir Dolsten Sells 2,600 ($389.5K) Of Agilent Technologies Inc [A]**
- Source: TradingView | 20251203T214039 | Somewhat-Bearish | Relevance: 100%
- A Director at Agilent Technologies Inc, Mikael Dolsten, sold 2,600 shares of the company's stock on December 1, 2025. The transaction was valued at $389,511, with shares sold at a price of $149.81 each. Following this sale, Dolsten's direct holdings in Agilent Technologies Inc stand at 4,973 shares.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $180 | $0 | 0% |
| 2025-11-25 | Citigroup | $185 | $165 | +12% |
| 2025-11-25 | UBS | $180 | $170 | +6% |
| 2025-11-25 | Wells Fargo | $175 | $150 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Overweight |
| 2025-11-25 | Citigroup | main | Buy |
| 2025-11-25 | UBS | main | Buy |
| 2025-11-25 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 10 ($1.37M) |
| Sells | 18 ($1.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (+0.1%)
- Blackrock Inc.: 9.2% (+1.0%)
- Massachusetts Financ: 4.4% (-6.0%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.3% (+4.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.5% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 7 raises (avg +12%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.16 elevated, pricing in significant growth expectations. Forward P/E 22.2x stretched relative to 10% growth. Quality metrics strong (ROE 21%, margin 19%). Analyst sentiment positive (7 raises, avg +12%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $39.2B |
| Beta | 1.27 |
| 52W Range | $96.43 - $160.27 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.16 |
| Forward P/E | 22.2 |
| Current P/E | 24.5 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -0.0% to -4.5% (-4.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.5pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.17x) but short-term weakness (below SMA20). MACD histogram bearish (-0.80), momentum weakening. RSI neutral at 46. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.50% (CS: 14) | Weak |
| RSI_14 | 46.0 | Neutral |
| MACD Histogram | -0.80 | Bearish |
| vs SMA20 | 0.977x | Below |
| vs SMA50 | 1.009x | Above |
| vs SMA200 | 1.174x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $145.49
- **Stop Loss:** $137.23 (5.7% risk)
- **Target:** $153.75 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 60
- **Position Value:** $8,729.40
- **Portfolio %:** 8.73%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-25 (Est: $1.37)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.58 | $1.59 | +0.4% |
| 2025Q3 | $1.37 | $1.37 | +0.2% |
| 2025Q2 | $1.26 | $1.31 | +3.6% |
| 2025Q1 | $1.27 | $1.31 | +3.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*